Winston-Salem, NC, United States of America

Daniel Yohannes

This inventor holds 10 USPTO granted patents and 13 published patent applications, plus 2 CIPO patents and 2 EPO patents. Top assignees: Targacept, Inc., Catalyst Biosciences, Inc., Wake Forest University. Active years: 2013-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Daniel Yohannes. Retrieved from https://idiyas.com/inventor/daniel-yohannes-zgksrtzz

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 10 (Patent Applications = 13)

% Patents Active = 20.0

CIPO Patents = 2 (Patent Applications = 4)

EPO Patents = 2 (Patent Applications = 12)

Average Co-Inventor Count = 6.4

ph-index = 2

Forward Citations = 13(Granted Patents)

Company Filing History:

Catalyst Biosciences, Inc.

patents

2 out of 525

Wake Forest University

patents

4. 1 out of 5

Tensive Controls, Inc.

patents

5. 1 out of 641

The UAB Research Foundation (The University of Alabama at Birmingham)

patents

6. 1 out of 834,601

Other

patents

where one patent can have more than one assignee

Years Active: 2013-2020

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10829519 - Angiotensin (1-7) analogs and methods relating thereto (2020-11-10),

2. 10716770 - Nicotinic receptor non-competitive antagonists (2020-07-21),

3. 10562844 - HYPDH inhibitors and methods of use for the treatment of kidney stones (2020-02-18),

4. 10258582 - Nicotinic receptor non-competitive antagonists (2019-04-16),

5. 9532974 - Nicotinic receptor non-competitive antagonists (2017-01-03),

6. 9173876 - Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide (2015-11-03),

7. 8901151 - Preparation and therapeutic applications of (2S, 3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]OCT-3-yl)-3,5-difluorobenzamide (2014-12-02),

8. 8809397 - Nicotinic receptor non-competitive antagonists (2014-08-19),

9. 8633227 - Synthesis and novel salt forms of (R)-3-((E)-pyrrolidin-3-yl)vinyl)-5-tetrahydropyran-4-yloxy)pyridine (2014-01-21),

10. 8476296 - Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]OCT-3-yl)-3,5-difluorobenzamide (2013-07-02),

Title: The Innovative Journey of Daniel Yohannes

Introduction

Daniel Yohannes, an accomplished inventor based in Winston-Salem, North Carolina, has made significant contributions to the field of biomedical innovations. With a portfolio boasting 10 patents, his work focuses on the development of therapeutic compositions that address critical health challenges.

Latest Patents

Among his latest patents is the invention related to Angiotensin (1-7) analogs and methods relating thereto. This innovation provides methods for creating these analogs which can be utilized as therapeutic compositions, particularly in the treatment of cancer. Another notable patent is centered on nicotinic receptor non-competitive antagonists. This invention encompasses compounds that modulate nicotinic receptors, serving as non-competitive antagonists along with their methods for use and pharmaceutical compositions.

Career Highlights

Daniel has been associated with several prominent companies throughout his career, including Targacept, Inc. and Catalyst Biosciences, Inc. His work in these organizations has not only advanced his research but also enriched the field of drug development and therapeutic solutions.

Collaborations

Throughout his professional journey, Daniel has collaborated with talented individuals such as Jason Daniel Speake and Srinivasa Rao Akireddy. These partnerships have been crucial in the advancement of his innovative projects, highlighting the importance of teamwork in the realm of scientific research.

Conclusion

Daniel Yohannes exemplifies the spirit of innovation in the biomedical sector. His patents and collaborations contribute significantly to the development of treatments that can potentially change lives. As he continues to push the boundaries of scientific research, his work remains a vital asset in the ongoing fight against various health conditions.

Profile summary based on public USPTO records.